REPORT OF THE NATIONAL CANCER REGISTRY

Jan, 2025

CANCER IN THE REPUBLIC OF MAURITIUS

INCIDENCE AND MORTALITY STUDY FOR 2023

MINISTRY OF HEALTH AND WELLNESS

AFRICAN CANCER REGISTRY NETWORK

WORLD HEALTH ORGANIZATION

FOREWORD

I am pleased to present the 2023 annual report of the Mauritius National Cancer Registry (MNCR), which highlights the latest data on cancer incidence and mortality in the Republic of Mauritius. This report is a testament to our commitment to addressing the growing burden of cancer, a major public health challenge for our nation.

The findings reveal rising cancer incidence, with prostate cancer leading among men and breast cancer among women. These trends align with global patterns and emphasize the need for targeted interventions. The MNCR continues to meet international standards for data collection and reporting, leveraging CanReg5 software and maintaining its status as a member of the African Cancer Registry Network.

This year's report coincides with the launch of the World Cancer Day campaign 2025–2027, "United by Unique". This initiative places people at the centre of care, encouraging innovative approaches to support individuals and communities in the fight against cancer.

I commend the MNCR team, led by Dr M. Koon Sun Pat, for their dedicated efforts in compiling this comprehensive report. Their work, supported by healthcare providers and international partners, ensures the delivery of accurate and high-quality data.

This report serves as a valuable resource for policymakers, researchers, and healthcare professionals, reaffirming our Ministry's commitment to reducing the impact of cancer and improving the health of our population.

Hon. A.K. Bachoo G.O.S.K
Minister of Health and Wellness

Date: 31 January 2025

ACKNOWLEDGEMENTS

The Mauritius National Cancer Registry (MNCR) is grateful to local and international partners that supported the organisation during the period under review.

1. Hon A.K. Bachoo, G.O.S.K, Minister of Health and Wellness
2. Mr S. Purmessur, Ag. Senior Chief Executive
3. Dr A. Dinassing, Ag. Director General Health Services
4. Mr R.K. Bunjun, Ag. Permanent Secretary
5. Dr (Mrs) P. Gungadin, Director Health Services
6. Mrs S. Kalasoptan-Chellen, Deputy Permanent Secretary
7. Mr Z. Nabee, Ag. Deputy Permanent Secretary
8. Mr J.L.D. Bhujoharry, Assistant Permanent Secretary
9. Dr T. Hemoo, Officer in Charge NCC
10. WHO Country Office, Port-Louis
11. African Cancer Registry Network (AFCRN)
12. International Association of Cancer Registries, IACR (Lyon)
13. International Agency for Research on Cancer, IARC (Lyon)

Our sincere thanks go to all units/departments who have assisted and contributed as sources of data for the registry namely:

1. National Cancer Centre
2. Laboratory archives, CHL
3. Regional hospital Health Records Department
4. Statistics Unit, MOHW
5. Overseas Treatment Unit, MOHW
6. The Civil Status Office, Prime Minister's Office

We are grateful for the continued support of the National Cancer Registry Steering Committee members: -

National Cancer Registry Steering Committee

- Dr A. Dinassing, Ag. Director General Health Services, MOHW (Chairman)
- Dr (Mrs) P. Gungadin, Director Health Services
- Dr (Mrs) J. Sonoo, Director Laboratory Services
- Dr M. Koon Sun Pat, NCR coordinator
- Dr (Mrs) S. Prasad-Chooromoney, Consultant-in-Charge (Clinical), NCC
- Dr A. Chinniah, Consultant-in-charge (RT), NCC
- Mr S. Munohur, Chief Health Records Officer, MOHW
- Mrs S. Chutoo, Ag. Chief Health Statistician, MOHW

We express our gratitude to the staff of the NCR Task Force for their coordination of activities, data collection and processing, as well as their contributions to the writing of the report:

National Cancer Registry Task Force

- Dr M. Koon Sun Pat, NCR Coordinator
- Mr M.F. Abdouramane, Health Care Assistant
- Mrs S.D. Chumun, Health Care Assistant

We are thankful to Dr S.S. Manraj and Mr S. Ramjaun former members of the National Cancer Registry for their legacy and trust in the new team.

As regards to the private sector, we are grateful to Wellkin Hospital, Twinmed Laboratory as well as the public and private pathologists for their collaboration in providing cancer data.

National Cancer Registry of Mauritius (2023)

1 EXECUTIVE SUMMARY

Incidence Data

During the year 2023, 2841 new cancer cases were diagnosed, 1205 were among males and 1636 among females. The main five cancer sites among males are as follows:

Site	Number	Percentage (%)	ASR – World (per 100,000)
Prostate	215	19.6	20.6
Colorectal	161	14.6	16.2
Lung	89	8.1	9.2
Mouth and Pharynx	65	6.0	6.8
Stomach	57	5.2	5.8

Among females, the five main cancer sites are:

Site	Number	Percentage (%)	ASR – World (per 100,000)
Breast	591	37.7	57.8
Colorectal	157	10.0	13.6
Corpus uteri	136	8.7	12.4
Ovary	104	6.6	11.2
Cervix uteri	99	6.3	9.9

The mean age for cancer incidence for males was 63.9 years and 60.0 years for females. Cancers among individuals aged 60 years and older accounted for 61.2% of all cases, with 68.5% occurring in males and 56.2% in females. Among those in their productive years (15 – 64 years), 57.1% of cancers were diagnosed in women and 45.6% in men. Paediatric cancers, affecting children aged 0–14 years, accounted for only 0.85% of all cases. Sex ratio (M/F) for cancer incidence was 0.74.

The total number of cancer cases has steadily increased over the years among both males and females, with the latter being more diagnosed with the disease than males. The overall ASR trend is increasing, particularly for prostate and colorectal cancers, while lung and stomach cancer rates have remained stable, and mouth and pharynx cancers have slightly decreased among males. Among females, breast cancer was the most common cancer, with a significant increase over time, followed by notable upward trends in colorectal, corpus uteri, and ovarian cancers. In contrast, cervical cancer rates decreased from 2001 to 2018 and have since stabilised.

Concerning the data quality indicators, there were no cases with unknown age recorded. Only 1.2% of cases had an unknown primary site. Regarding the basis of diagnosis, microscopic verification (MV) was performed for 90.1% of cases, and clinical investigations (CLIN) accounted for 9.8% of cases.

In 2023, out of a total of 11,839 deaths in Mauritius, 1,546 were attributed to cancer, with 754 deaths occurring in males and 791 in females, resulting in a male-to-female mortality sex ratio of 0.95. Prostate cancer (n=118, 15.6%) was the leading cause of cancer deaths among males, followed by colorectal (n=161, 14.6%) and lung cancer (n=107, 14.2%). Among females, breast cancer (n=225, 28.4%) remained the primary cause of cancer deaths, followed by colorectal (n=91, 11.5%) and lung cancer (n=64, 8.1%). The overall Mortality/Incidence (MI) ratio was 0.63 for males and 0.48 for females.

2 BACKGROUND AND POPULATION

2.1 BACKGROUND

Since its independence, Mauritius has undergone an epidemiological transition, marked by a shift in the pattern of diseases. The country moved from being dominated by infectious and vector-borne diseases, such as tuberculosis and malaria, to one characterized by a predominance of chronic and non-communicable diseases (NCDs), including cancer. This transition underscores the growing importance of cancer surveillance and the role of the Mauritius National Cancer Registry (MNCR) in addressing the increasing cancer burden.

The MNCR was established in 1993 under the leadership of Dr Shyam Manraj with support from French cooperation. Initially, the registry functioned as a pathology-based registry housed at the Central Health Laboratory, Victoria Hospital. It gained affiliation with the International Association of Cancer Registries (IACR) in 1997, and its first report, covering the period 1989–1996, was published in 1999.

The MNCR transitioned to a population-based registry in 2001. Data processing initially used CanReg software, with the CanReg5 version implemented in 2010 to enhance data management and analysis. Demonstrating the quality of its data, the MNCR's information was included in the 12th edition of the *Cancer Incidence in Five Continents* publication, a globally recognized series showcasing reliable and high-quality cancer registry data.

The registry has also contributed to the global cancer registration community by hosting the 33rd Annual Meeting of the IACR in 2011 at Balaclava. It became a member of the African Cancer Registry Network (AFCRN) in 2013, further strengthening its regional and international collaborations.

The primary objective of the MNCR is to systematically collect, analyse, and disseminate data on cancer incidence, mortality and trends in the Republic of Mauritius. This information is crucial for monitoring the cancer burden, informing public health strategies, guiding resource allocation, and evaluating the effectiveness of cancer prevention and control programs.

2.2 POPULATION

The Registry covers the entire population of the Republic of Mauritius including Rodrigues and the other outer islands.

The estimated average mid-year population was 1,260,767 (622,817 males and 637,950 females) in 2023 according to the Health Statistics Report 2023 of the Ministry of Health and Wellness.



Fig 1. Estimated average annual population for the year 2023

Fig 2. Geographical area covered: The Republic of Mauritius

3 METHODS

3.1 SOURCES OF DATA

Data for 2023 was collected retrospectively from multiple sources. The primary data sources included the radiotherapy patient register, regional hospital records, and laboratory archives at the Central Health Laboratory (CHL), Victoria Hospital, which were utilised to identify cancer cases. At the CHL, cancer cases were retrieved from the histopathology department (including histopathology and bone marrow biopsy reports), biochemistry department (tumour markers), and immunochemistry department (immunochemistry reports). This data was further supplemented by information from the Overseas Treatment Unit (OTU) and some private pathology services (Twinmed and C-Care Welkin).



Fig.3 Organigram of the sources of information where data is collected

3.2 METHODS OF DATA COLLECTION

Similar to the previous year, data collection was conducted passively. However, since July 2024, the MNCR has also adopted an active data collection approach, with staff directly abstracting information from medical records at the National Cancer Centre in Solferino.

3.3 DEATH CERTIFICATES

Similar to the previous year the MNCR received only anonymised data from the Civil Status Office for the period of the study. Consequently, we were not able to retrieve Death Certificate Only (DCO) cases. Once data containing names and National Identification Numbers (NID) becomes available, the MNCR will update the registry accordingly.

3.4 VARIABLE

The variables abstracted include the patient's administrative details, tumour-specific information and the sources of data. The mandatory variables are: surname, first name, sex, age, date of birth, address, incidence date, topography, morphology, behaviour, and basis of diagnosis.

Benign conditions (thyrotoxicosis, keloid, adenomas), with the exception of brain tumours and cancer cases amongst foreigners were excluded.

3.5 CLASSIFICATION AND CODING

Data was coded using the ICD-O 3rd edition and ICD-10 classifications, then analysed and stored in the CanReg5 software. When TNM staging was unavailable for certain sites, Essential TNM was utilised, particularly during active surveillance efforts.

3.6 THE DATABASE

The registry uses CanReg5 software (http://www.iacr.com.fr/CanReg5) for data entry, management and analysis.
The 'IARCcrgTOOL' software was run to check for any inconsistency on the data. Population estimates data available by sex and 5-year age groups have been utilised as denominators to calculate incidence.

3.7 CONFIDENTIALITY

The registry adheres to the guidelines of the IACR/IARC (2004) with respect to the preservation of confidentiality in connection with or during the process of collection, storage, use and transmission of identifiable data. Requests for the release of data should be made in writing to

the registry; requests for data involving identification of individual subjects require special permission, involving appropriate safeguards for confidentiality.

3.8 STATISTICAL METHODS

3.8.1 Age-specific rate

The age-specific rate is calculated simply by dividing the number of cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period.

For cancer, the result is usually expressed as an annual rate per 100,000 person-years.

3.8.2 Crude incidence rate

The crude incidence rate is the number of new cases of cancer diagnosed in a specified population during a given time period, divided by the total size of that population, and is often expressed per 100,000 people. It reflects the actual burden of disease in the population, making it useful for resource planning and public health management. However, it is influenced by the age structure of the population, which can limit its use for comparisons between populations with different demographic profiles.

3.8.3 Age-standardisation rate

An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure.

Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of dying from cancer.

The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the standard population.

The ASR is also expressed per 100,000.

3.8.4 Cumulative risk

Cumulative mortality is the probability or risk of individuals dying from the disease during a specified period.

For cancer, it is expressed as the number of new born children (out of 100, or 1000) who would be expected to die from a particular cancer before the age of 75 or (65 or 70) if they had the rates of cancer observed in the period in the absence of competing causes.

Like the age standardised rate, it permits comparisons between populations of different age structures.

4 RESULTS

In 2023, the cancer registry registered 2841 cases of cancers: 1205 among men and 1636 among women.

4.1 NUMBER OF CASES IN PERIOD, BY AGE GROUP AND SEX



Fig 4a. Bar chart, distribution of cases by age group and sex



Fig 4b. Pie chart, distribution of cases by age group and sex

Figures 4a and 4b illustrate that the majority of cancer cases occur in the 50–69 and 70+ age groups. In contrast, paediatric cancers (0–14 years) are relatively rare compared to the other age categories.

4.2 TRENDS OF THE NUMBER OF CASES BY 3- YEAR PERIOD



Fig 5. Average Number of cases by 3-year period

The total number of cancer cases has been steadily increasing over the years among both males and females. Overall, the number of cancer cases is higher among females than males for each period.

4.3 THE MOST COMMON CANCERS

In men, prostate is the most commonly diagnosed malignancy (n=215, 19.6%) cases, followed by colon, rectum, anus (n=161, 14.6%) and lungs (n= 89, 8.1%)).

In women, breast is the most commonly diagnosed malignancy (n= 591, 37.7%), followed by colon, rectum, anus (n=157, 10.0%) and corpus uteri (n= 136, 8.7%).



Fig 6a. Top 10 cancers, both sexes (Number of cases)



Fig 6b. Top 10 cancers, both sexes (Age-standardized rate per 100,000)

Figures 6a and 6b show the top 10 cancer sites among both sexes in number of cases and in ASR.

4.4 TOP 10 CANCERS, BY NUMBER OF CASES, PERCENTAGE, CRUDE INCIDENCE RATE AND BY AGE STANDARDIZED INCIDENCE RATE



Fig 7. Top 10 cancers, by number of cases, percentage, crude incidence rate and by age standardized incidence rate

Figure 7 illustrates the top 10 most common cancer sites among males and females in terms of number of cases, percentage, crude incidence rate and by age standardized incidence rate. The three most common sites among males are: prostate, colon-rectum-anus and lungs, while among females, they are: breast, colon-rectum-anus and corpus uteri.

4.5 Trends in Age Standardised Incidence Rate from 2001 to 2023, by gender and by the most common (top 5) cancer sites



Fig 8. Trends in Age Standardised Incidence Rate from 2001 to 2023 by gender

Figure 8 illustrates an upward trend in the overall ASR. The ASR for females consistently exceeds that of males, indicating higher cancer incidence among women for the different periods.



Fig 9. Trends in Age Standardised Incidence Rate from 2001 to 2023 by the most common sites among male

Trends in the age standardised incidence rates of prostate and colorectal cancers have increased over the last two decades. Lung and stomach cancers have remained stable while mouth and pharynx neoplasm has slightly decreased over time.



Fig 10. Trends in Age Standardised Incidence Rate from 2001 to 2023 by the most common sites among female

Breast cancer is by far the most common cancer among women, with a significative increase of its ASR over time. Colorectal, together with corpus uteri and ovary trends have also increased significantly. Cervical cancer rates have decreased from 2001 to 2018 and have stabilised over the last few years.

4.6 COMPARISON OF SUMMARY RATES WITH OTHER REGIONAL COUNTRIES

Figure 11 shows a comparison of the age standardised incidence rates in the Mauritius National Cancer Registry (2023) with those observed in Reunion Island (2022), South Africa (2022) and Kenya (2022) (GLOBOCAN, 2022). The top five most common cancer sites among males and females were compared with the regional countries having the closest socio-economic characteristics to Mauritius.





Fig 11. Comparison with other countries

4.7 Basis of Diagnosis (DCO / Clinical / MV) by site

Table 1 shows the percentage of cases at the major sites that were registered on the basis of information from a death certificate only (DCO) and with morphological verification (MV) - that is, based on cytology or histology (of the primary tumour, or a metastasis).

Data Quality Indicators

MALE

SITE	Cases	% Total	ASR(se)	MV(%)	CLIN(%)	DCO(%)	ICD10
All sites but C44	1099	91.20	115.12 (3.56)	89.90	10.10	0	ALLbC44
Mouth & pharynx	65	5.39	6.86 (0.86)	95.38	4.62	0	C00−14
Oesophagus	35	2.90	3.68 (0.63)	91.43	8.57	0	C15
Stomach	57	4.73	5.80 (0.78)	91.23	8.77	0	C16
Colon, rectum, anus	161	13.36	16.25 (1.30)	93.79	6.21	0	C18−21
Liver	28	2.32	2.72 (0.52)	85.71	14.29	0	C22
Pancreas	33	2.74	3.36 (0.59)	63.64	36.36	0	C25
Larynx	37	3.07	3.54 (0.59)	89.19	10.81	0	C32
Lung, trachea, bronchus	89	7.39	9.18 (0.99)	86.52	13.48	0	C33−34
Pleura & other thoracic	10	0.83	1.20 (0.40)	80.00	20.00	0	C37−38
Melanoma of skin	6	0.50	0.64 (0.27)	100.00	0.00	0	C43
Breast	7	0.58	0.71 (0.27)	85.71	14.29	0	C50
Prostate	215	17.84	20.57 (1.42)	85.58	14.42	0	C61
Testis	24	1.99	3.41 (0.71)	91.67	8.33	0	C62
Kidney & urinary NOS	34	2.82	3.62 (0.63)	91.18	8.82	0	C64−66,68
Bladder	48	3.98	4.82 (0.70)	95.83	4.17	0	C67
Brain & nervous sytem	26	2.16	3.06 (0.62)	100.00	0.00	0	C70−72
Thyroid	6	0.50	0.66 (0.27)	100.00	0.00	0	C73
Ill−defined	62	5.15	6.63 (0.85)	79.03	20.97	0	C76−80
Lymphoma	53	4.40	6.50 (0.95)	100.00	0.00	0	C81−85,90,88,96
Leukaemia	19	1.58	2.35 (0.59)	100.00	0.00	0	C91−95

FEMALE

SITE	Cases	% Total	ASR(se)	MV(%)	CLIN(%)	DCO(%)	ICD10
All sites but C44	1569	95.90	155.45 (4.23)	89.23	10.77	0	ALLbC44
Mouth & pharynx	42	2.57	3.97 (0.63)	100.00	0.00	0	C00−14
Oesophagus	9	0.55	0.77 (0.27)	88.89	11.11	0	C15
Stomach	42	2.57	3.42 (0.54)	100.00	0.00	0	C16
Colon, rectum, anus	157	9.60	13.61 (1.15)	91.08	8.92	0	C18−21
Liver	22	1.34	1.89 (0.42)	81.82	18.18	0	C22
Pancreas	28	1.71	3.24 (0.66)	35.71	64.29	0	C25
Larynx	9	0.55	0.88 (0.30)	66.67	33.33	0	C32
Lung, trachea, bronchus	57	3.48	5.12 (0.70)	73.68	26.32	0	C33−34
Pleura & other thoracic	1	0.06	0.09 (0.09)	100.00	0.00	0	C37−38
Melanoma of skin	3	0.18	0.28 (0.17)	100.00	0.00	0	C43
Breast	591	36.12	57.85 (2.48)	95.26	4.74	0	C50
Cervix	99	6.05	9.89 (1.03)	91.92	8.08	0	C53
Corpus & Uterus NOS	136	8.31	12.45 (1.11)	97.79	2.21	0	C54−55
Ovary & adnexa	104	6.36	11.25 (1.16)	48.08	51.92	0	C56
Kidney & urinary NOS	22	1.34	2.21 (0.50)	95.45	4.55	0	C64−66,68
Bladder	15	0.92	1.40 (0.38)	93.33	6.67	0	C67
Brain & nervous sytem	50	3.06	5.09 (0.76)	94.00	6.00	0	C70−72
Thyroid	22	1.34	2.75 (0.62)	90.91	9.09	0	C73
Ill−defined	48	2.93	4.72 (0.76)	79.17	20.83	0	C76−80
Lymphoma	30	1.83	3.04 (0.59)	100.00	0.00	0	C81−85,90,88,96
Leukaemia	17	1.04	3.74 (1.07)	100.00	0.00	0	C91−95

Table 1.

5 MORTALITY

This report on cancer mortality in the Republic of Mauritius represents all the cancer deaths registered for the year 2023.
After each calendar year, an anonymous listing of all death that occurred in the Republic of Mauritius from the Civil Status Office is transferred to the Statistical department of the Ministry of Health & Wellness. The causes of death are coded according to the ICD-10 classification before being handled to the National Cancer Registry. The data is further checked for misclassification of cancer cases and recoded whenever necessary. Hence, cancer patients dying from other causes of death than neoplasm were also included in the mortality report.

Deaths due to benign neoplasms (except brain) are excluded from the study. Analysis of cancer data is then performed using STATA software and the results tabulated using EXCEL software.

Main conclusions of the cancer mortality study for 2023 are as follows:

1546 Deaths due to cancer have been registered during the year 2023, **754** in males and **791** in women. The Mortality/Incidence (MI) ratio is **0.63** for males and **0.48** for females.

The tables below illustrate mortality due to the ten main cancer sites among males and females.

MOST COMMON SITES FOR MORTALITY CASES IN 2023 (MALE)

Site	Number	Percentage (%)	Crude Mortality Rate/10^5	ASR (World) /10^5
Prostate	118	15.6	18.9	11.9
Colorectal	108	14.3	17.3	11.0
Trachea, Bronchus & Lung	107	14.2	17.2	10.7
Stomach	44	5.8	7.1	4.4
Pancreas	42	5.6	6.7	4.1
Liver& Intra-hepatic bile ducts	36	4.8	5.8	3.6
Brain	28	3.7	4.5	3.1
Oesophagus	19	2.5	3.1	1.9
Leukaemias	19	2.5	3.1	2.3
Bladder	18	2.4	2.9	1.7
Larynx	17	2.3	2.7	1.7
Kidney, Pelvis& Ureter	16	2.1	2.6	1.6
Others	182	24.1	29.2	19.1
TOTAL	754	100	121.1	77.1

MOST COMMON SITES FOR MORTALITY CASES IN 2023 (FEMALE)

Site	Number	Percentage (%)	Crude Mortality Rate/10	ASR (World) /10^5
Breast	225	28.4	35.3	20.2
Colorectal	91	11.5	14.3	7.0
Trachea, Bronchus& Lung	64	8.1	10.0	5.2
Corpus Uteri	51	6.4	8.0	4.2
Ovary	51	6.4	8.0	4.6
Cervix Uteri	37	4.7	5.8	3.1
Pancreas	26	3.3	4.1	2.2
Liver& Intra-hepatic bile	25	3.2	3.9	2.1
Brain	23	2.9	3.6	1.7
Stomach	20	2.5	3.1	1.9
Leukaemias	17	2.1	2.7	1.0
NHML	12	1.5	1.9	0.8
OTHERS	149	18.8	23.4	16.1
TOTAL	791	100	124.0	70.3

6 APPENDIX

6.1 TABLES

6.1.1 Estimated mid-year population for Mauritius and Rodrigues 2023

Ages	Male	Female	World Population
0 - 4	32149	31280	: 12000
5 - 9	33158	31789	: 10000
10 - 14	37077	36233	: 9000
15 - 19	45044	43415	: 9000
20 - 24	48876	47128	: 8000
25 - 29	47815	47048	: 8000
30 - 34	47720	46226	: 6000
35 - 39	41223	39871	: 6000
40 - 44	48574	47091	: 6000
45 - 49	44532	43605	: 6000
50 - 54	39263	39039	: 5000
55 - 59	44054	45624	: 4000
60 - 64	38808	42358	: 4000
65 - 69	30555	35088	: 3000
70 - 74	22782	28299	: 2000
75 - 79	11849	16939	: 1000
80 - 84	5531	9114	: 500
85 +	3807	7803	: 500
Total	**622817**	**637950**	**: 100000**

6.1.2 Incident cases by age group in 2023 (Male)

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	(%)	ICD (10th)
Lip	2	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0.2	C00
Tongue	24	0	0	0	0	0	0	0	0	1	1	2	5	2	3	6	1	1	2	0	2.2	C01-02
Mouth	12	0	0	0	0	0	0	0	0	0	0	1	1	1	2	0	3	2	1	1	1.1	C03-06
Salivary glands	8	0	0	0	0	0	0	0	0	0	0	1	0	3	2	1	1	0	0	0	0.7	C07-08
Tonsil	9	0	0	0	0	0	0	0	0	0	0	1	1	0	3	0	3	0	1	0	0.8	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0.2	C10
Nasopharynx	3	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0	0.3	C11
Hypopharynx	3	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0	0	0	0.3	C12-13
Pharynx unspecified	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0.2	C14
Oesophagus	35	0	0	0	0	0	0	1	0	0	2	3	2	6	5	6	5	2	1	2	3.2	C15
Stomach	57	0	0	0	0	0	0	0	0	1	3	1	6	6	8	13	10	5	2	2	5.2	C16
Small intestine	8	0	0	0	0	0	0	0	0	0	0	0	2	1	2	2	0	0	0	1	0.7	C17
Colon	121	0	0	0	0	0	0	0	1	0	2	9	6	17	17	17	24	11	9	8	11	C18
Rectum	40	0	0	0	0	0	0	1	0	2	0	0	1	5	7	5	9	6	1	3	3.6	C19-20
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	28	0	0	0	0	0	0	0	1	0	0	0	1	4	3	5	6	4	2	2	2.5	C22
Gallbladder etc.	4	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	1	0	0.4	C23-24
Pancreas	33	0	0	0	0	0	0	0	0	0	0	1	4	6	9	7	2	3	0	1	3	C25
Nose, sinuses etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-31
Larynx	37	0	0	0	0	0	0	0	0	0	1	1	0	5	7	9	8	4	2	0	3.4	C32
Trachea, bronchus and lung	89	0	0	0	0	0	0	0	0	2	4	5	9	7	16	14	16	10	3	3	8.1	C33-34
Other thoracic organs	10	0	0	0	0	1	0	1	1	1	0	0	0	2	1	1	2	0	0	0	0.9	C37-38
Bone	6	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	2	0	1	0	0.5	C40-41
Melanoma of skin	6	0	0	0	0	0	1	0	0	0	0	0	0	1	2	0	0	1	1	0	0.5	C43
Other skin	106	0	0	1	1	0	2	0	1	1	2	5	10	12	10	14	20	12	5	10	9.6	C44
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0.2	C45
Kaposi sarcoma	1	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C46
Connective and soft tissue	10	0	0	0	0	0	0	0	1	0	1	2	1	0	1	3	0	0	0	1	0.9	C47,C49
Breast	7	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2	0	0	2	0	0.6	C50
Penis	7	0	0	0	0	0	0	0	0	0	2	1	3	0	0	0	1	0	0	0	0.6	C60
Prostate	215	0	0	0	0	0	0	0	0	0	0	1	4	10	28	41	49	43	23	16	19.6	C61
Testis	24	0	0	0	0	0	4	6	1	6	1	2	0	3	0	0	1	0	0	0	2.2	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	34	0	0	0	0	0	0	0	0	1	0	3	3	5	9	3	5	0	2	3	3.1	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	48	0	0	0	0	0	0	0	1	1	1	2	2	10	8	10	5	3	4	1	4.4	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0.2	C69
Brain, nervous system	26	0	0	0	0	1	2	0	1	1	1	3	2	2	2	8	1	1	0	1	2.4	C70-72
Thyroid	6	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	1	1	1	0	0.5	C73
Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	6	0	0	0	1	1	0	1	1	0	0	1	0	0	0	0	0	1	0	0	0.5	C81
Non-Hodgkin lymphoma	38	0	0	1	1	1	1	0	2	1	3	5	3	2	6	3	3	4	1	1	3.5	C82-85,C96
Immunoproliferative diseases	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1	C88
Multiple myeloma	8	0	0	0	0	0	0	0	0	0	1	1	0	3	1	1	0	1	0	0	0.7	C90
Lymphoid leukaemia	6	0	0	1	0	0	1	0	0	0	0	0	0	0	1	1	2	0	0	0	0.5	C91
Myeloid leukaemia	7	0	0	0	0	0	0	0	0	0	1	0	0	2	0	2	0	1	0	1	0.6	C92-94
Leukaemia unspecified	6	0	0	0	1	0	1	0	0	0	1	0	0	1	0	0	0	1	1	0	0.5	C95
Myeloproliferative disorders	33	0	0	0	0	3	0	0	2	3	2	3	3	3	4	6	1	1	1	1	3	MPD
Myelodysplastic syndromes	7	0	0	0	0	0	0	0	0	0	0	1	0	2	0	1	1	1	0	1	0.6	MDS
Other and unspecified	66	0	0	0	0	0	0	1	1	1	3	4	6	8	14	13	6	2	3	4	6	O&U
All sites	1205	0	0	3	4	7	13	12	14	22	34	62	79	132	177	198	189	126	70	63	109.6	ALL
All sites but C44	1099	0	0	2	3	7	11	12	13	21	32	57	69	120	167	184	169	114	65	53	100	ALLbC44

6.1.3 Incident cases by age group in 2023 (Female)

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	(%)	ICD (10th)
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C00
Tongue	16	0	0	0	0	0	0	0	2	0	0	0	2	0	7	2	1	1	0	1	1	C01-02
Mouth	11	0	0	0	0	0	0	0	0	0	3	0	1	0	1	4	1	1	0	0	0.7	C03-06
Salivary glands	4	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	1	1	0	0.3	C07-08
Tonsil	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0.2	C09
Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C10
Nasopharynx	2	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0.1	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1	C12-13
Pharynx unspecified	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0.2	C14
Oesophagus	9	0	0	0	0	0	0	0	1	0	0	1	0	2	0	0	3	0	1	1	0.6	C15
Stomach	42	0	0	0	0	0	0	0	0	0	0	2	1	4	6	12	5	5	3	4	2.7	C16
Small intestine	8	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	1	1	3	0	0.5	C17
Colon	126	0	0	0	1	1	0	0	1	2	5	2	12	9	17	20	15	19	13	9	8	C18
Rectum	25	0	0	0	0	0	0	1	0	1	0	0	0	2	5	3	8	1	3	1	1.6	C19-20
Anus	6	0	0	0	0	0	0	0	0	0	0	2	1	1	0	0	1	1	0	0	0.4	C21
Liver	22	0	0	0	0	0	0	0	0	1	1	1	0	3	2	5	4	2	0	3	1.4	C22
Gallbladder etc.	10	0	0	0	0	0	0	0	0	0	0	1	1	1	3	3	0	0	1	0	0.6	C23-24
Pancreas	28	0	0	0	1	1	1	3	0	1	1	3	2	2	3	3	4	0	3	0	1.8	C25
Nose, sinuses etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-31
Larynx	9	0	0	0	0	0	0	0	0	0	1	1	1	1	0	4	0	0	1	0	0.6	C32
Trachea, bronchus and lung	57	0	0	0	0	0	0	1	0	1	1	5	1	7	13	9	11	4	3	1	3.6	C33-34
Other thoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.1	C37-38
Bone	4	0	1	0	0	0	0	2	1	0	0	0	0	0	0	0	0	0	0	0	0.3	C40-41
Melanoma of skin	3	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	1	0.2	C43
Other skin	67	0	0	0	0	0	2	2	0	0	2	2	5	7	7	7	9	9	7	8	4.3	C44
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0.1	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective and soft tissue	9	0	0	0	0	0	1	0	0	0	0	2	0	1	4	0	1	0	0	0	0.6	C47,C49
Breast	591	0	0	0	0	0	0	3	12	26	40	50	70	83	76	72	79	47	17	16	37.7	C50
Vulva	7	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	1	1	1	2	0.4	C51
Vagina	5	0	0	0	1	0	0	0	0	0	0	0	0	2	1	0	0	0	1	0	0.3	C52
Cervix uteri	99	0	0	0	0	0	0	0	6	3	11	11	9	11	8	12	16	8	1	3	6.3	C53
Corpus uteri	113	0	0	0	0	0	0	1	2	1	3	3	11	21	24	13	17	7	6	4	7.2	C54
Uterus unspecified	23	0	0	0	0	0	0	0	1	2	2	0	2	0	8	2	3	0	3	0	1.5	C55
Ovary	104	0	0	0	1	1	2	3	7	4	4	10	12	13	20	11	8	2	3	3	6.6	C56
Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	22	0	0	0	0	1	1	0	1	1	0	2	0	0	2	9	2	2	0	1	1.4	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	15	0	0	0	0	0	0	0	0	2	1	0	1	3	3	0	0	2	1	2	1	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	3	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	C69
Brain, nervous system	50	0	0	0	1	0	2	0	0	1	2	3	7	6	4	16	4	4	0	0	3.2	C70-72
Thyroid	22	0	0	0	0	2	0	2	0	2	2	4	2	1	1	3	1	0	1	1	1.4	C73
Adrenal gland	2	0	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C75
Hodgkin disease	4	0	0	0	0	0	1	0	0	1	0	0	0	1	0	0	1	0	0	0	0.3	C81
Non-Hodgkin lymphoma	15	0	0	0	0	1	1	0	0	1	1	0	1	3	3	1	1	1	1	0	1	C82-85,C96
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	11	0	0	0	0	0	0	0	0	0	1	0	1	0	3	2	1	1	1	1	0.7	C90
Lymphoid leukaemia	3	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.2	C91
Myeloid leukaemia	6	0	0	0	0	0	0	0	0	0	1	0	1	1	1	1	1	0	0	0	0.4	C92-94
Leukaemia unspecified	8	0	4	1	1	0	0	0	0	1	0	0	0	0	0	0	0	1	0	0	0.5	C95
Myeloproliferative disorders	9	0	0	0	0	0	0	0	0	0	0	0	1	0	3	3	2	0	0	0	0.6	MPD
Myelodysplastic syndromes	4	0	0	0	0	0	1	0	0	0	0	0	1	0	0	2	0	0	0	0	0.3	MDS
Other and unspecified	49	0	1	0	0	0	0	1	1	1	2	3	2	5	10	8	6	5	2	2	3.1	O&U
All sites	1636	0	12	1	6	7	12	19	36	54	85	109	150	195	242	230	209	127	77	65	104.3	ALL
All sites but C44	1569	0	12	1	6	7	10	17	36	54	83	107	145	188	235	223	200	118	70	57	100	ALLbC44

6.1.4 Incidence by 100,000 by age group in 2023 (Male)

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	2	0	0	0	0	0	0	2.1	0	0	0	0	0	0	0	0	0	8.4	0	0	0.32	0.2	0.01	0.01	0.3	C00
Tongue	24	0	0	0	0	0	0	0	0	2.4	2.1	4.5	12.7	4.5	7.7	19.6	4.4	8.4	36.2	0	3.85	2.2	0.17	0.29	2.6	C01-02
Mouth	12	0	0	0	0	0	0	0	0	0	0	2.2	2.5	2.3	5.2	0	13.2	16.9	18.1	26.3	1.93	1.1	0.06	0.13	1.2	C03-06
Salivary glands	8	0	0	0	0	0	0	0	0	0	0	2.2	0	6.8	5.2	3.3	4.4	0	0	0	1.28	0.7	0.07	0.11	0.8	C07-08
Tonsil	9	0	0	0	0	0	0	0	0	0	0	2.2	2.5	0	7.7	0	13.2	0	18.1	0	1.45	0.8	0.06	0.13	0.9	C09
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	0	2.3	2.6	0	0	0	0	0	0.32	0.2	0.02	0.02	0.2	C10
Nasopharynx	3	0	0	0	0	0	0	0	0	0	2.1	0	2.5	0	0	3.3	0	0	0	0	0.48	0.3	0.02	0.04	0.3	C11
Hypopharynx	3	0	0	0	0	0	0	0	0	0	0	2.2	0	2.3	2.6	0	0	0	0	0	0.48	0.3	0.04	0.04	0.3	C12-13
Pharynx unspecified	2	0	0	0	0	0	0	0	0	0	0	0	0	2.3	0	3.3	0	0	0	0	0.32	0.2	0.01	0.03	0.2	C14
Oesophagus	35	0	0	0	0	0	0	2.1	0	0	4.1	6.7	5.1	13.6	12.9	19.6	21.9	16.9	18.1	52.5	5.62	3.2	0.22	0.43	3.7	C15
Stomach	57	0	0	0	0	0	0	0	0	2.4	6.2	2.2	15.3	13.6	20.6	42.5	43.9	42.2	36.2	52.5	9.15	5.2	0.3	0.73	5.8	C16
Small intestine	8	0	0	0	0	0	0	0	0	0	0	0	5.1	2.3	5.2	6.5	0	0	0	26.3	1.28	0.7	0.06	0.1	0.9	C17
Colon	121	0	0	0	0	0	0	0	2.1	0	4.1	20.2	15.3	38.6	43.8	55.6	105.3	92.8	162.7	210.1	19.43	11	0.62	1.43	12.2	C18
Rectum	40	0	0	0	0	0	0	2.1	0	4.9	0	0	2.5	11.3	18	16.4	39.5	50.6	18.1	78.8	6.42	3.6	0.19	0.47	4	C19-20
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21
Liver	28	0	0	0	0	0	0	0	2.1	0	0	0	2.5	9.1	7.7	16.4	26.3	33.8	36.2	52.5	4.5	2.5	0.11	0.32	2.7	C22
Gallbladder etc.	4	0	0	0	0	0	0	0	0	0	0	0	0	0	2.6	0	0	16.9	18.1	0	0.64	0.4	0.01	0.01	0.4	C23-24
Pancreas	33	0	0	0	0	0	0	0	0	0	0	2.2	10.2	13.6	23.2	22.9	8.8	25.3	0	26.3	5.3	3	0.25	0.4	3.4	C25
Nose, sinuses etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-31
Larynx	37	0	0	0	0	0	0	0	0	0	2.1	2.2	0	11.3	18	29.5	35.1	33.8	36.2	0	5.94	3.4	0.17	0.49	3.5	C32
Trachea, bronchus and lung	89	0	0	0	0	0	0	0	0	4.9	8.2	11.2	22.9	15.9	41.2	45.8	70.2	84.4	54.2	78.8	14.29	8.1	0.52	1.1	9.2	C33-34
Other thoracic organs	10	0	0	0	0	2.2	0	2.1	2.1	2.4	0	0	0	4.5	2.6	3.3	8.8	0	0	0	1.61	0.9	0.08	0.14	1.2	C37-38
Bone	6	0	0	0	0	0	0	0	0	0	0	0	2.5	0	2.6	3.3	8.8	0	18.1	0	0.96	0.5	0.03	0.09	0.6	C40-41
Melanoma of skin	6	0	0	0	0	0	2	0	0	0	0	0	0	2.3	5.2	0	0	8.4	18.1	0	0.96	0.5	0.05	0.05	0.6	C43
Other skin	106	0	0	3	2.7	0	4.1	0	2.1	2.4	4.1	11.2	25.5	27.2	25.8	45.8	87.8	101.3	90.4	262.7	17.02	9.6	0.54	1.21	11.4	C44
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4.4	8.4	0	0	0.32	0.2	0	0.02	0.2	C45
Kaposi sarcoma	1	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0.16	0.1	0.01	0.01	0.2	C46
Connective and soft tissue	10	0	0	0	0	0	0	0	2.1	0	2.1	4.5	2.5	0	2.6	9.8	0	0	0	26.3	1.61	0.9	0.07	0.12	1.2	C47,C49
Breast	7	0	0	0	0	0	0	0	0	0	0	0	2.5	0	5.2	6.5	0	0	36.2	0	1.12	0.6	0.04	0.07	0.7	C50
Penis	7	0	0	0	0	0	0	0	0	0	4.1	2.2	7.6	0	0	0	4.4	0	0	0	1.12	0.6	0.07	0.09	0.9	C60
Prostate	215	0	0	0	0	0	0	0	0	0	0	2.2	10.2	22.7	72.2	134.2	215.1	362.9	415.8	420.3	34.52	19.6	0.54	2.28	20.6	C61
Testis	24	0	0	0	0	0	8.2	12.5	2.1	14.6	2.1	4.5	0	6.8	0	0	4.4	0	0	0	3.85	2.2	0.25	0.28	3.4	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63
Kidney	34	0	0	0	0	0	0	0	0	2.4	0	6.7	7.6	11.3	23.2	9.8	21.9	0	36.2	78.8	5.46	3.1	0.26	0.42	3.6	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	48	0	0	0	0	0	0	0	2.1	2.4	2.1	4.5	5.1	22.7	20.6	32.7	21.9	25.3	72.3	26.3	7.71	4.4	0.3	0.57	4.8	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	2	0	0	0	0	0	0	0	0	0	0	0	2.5	0	0	3.3	0	0	0	0	0.32	0.2	0.01	0.03	0.2	C69
Brain, nervous system	26	0	0	0	0	2.2	4.1	0	2.1	2.4	2.1	6.7	5.1	4.5	5.2	26.2	4.4	8.4	0	26.3	4.17	2.4	0.17	0.32	3.1	C70-72
Thyroid	6	0	0	0	0	0	0	0	0	0	2.1	4.5	0	0	0	0	4.4	8.4	18.1	0	0.96	0.5	0.03	0.05	0.7	C73
Adrenal gland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C74
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75
Hodgkin disease	6	0	0	0	2.7	2.2	0	2.1	2.1	0	0	2.2	0	0	0	0	0	8.4	0	0	0.96	0.5	0.06	0.06	1	C81
Non-Hodgkin lymphoma	38	0	0	3	2.7	2.2	2	0	4.2	2.4	6.2	11.2	7.6	4.5	15.5	9.8	13.2	33.8	18.1	26.3	6.1	3.5	0.31	0.42	4.6	C82-85,C96
Immunoproliferative diseases	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	8.4	0	0	0.16	0.1	0	0	0.1	C88
Multiple myeloma	8	0	0	0	0	0	0	0	0	0	2.1	2.2	0	6.8	2.6	3.3	0	8.4	0	0	1.28	0.7	0.07	0.08	0.8	C90
Lymphoid leukaemia	6	0	0	3	0	0	2	0	0	0	0	0	0	0	2.6	3.3	8.8	0	0	0	0.96	0.5	0.04	0.1	0.8	C91
Myeloid leukaemia	7	0	0	0	0	0	0	0	0	0	2.1	0	0	4.5	0	6.5	0	8.4	0	26.3	1.12	0.6	0.03	0.07	0.7	C92-94
Leukaemia unspecified	6	0	0	0	2.7	0	2	0	0	0	2.1	0	0	2.3	0	0	0	8.4	18.1	0	0.96	0.5	0.05	0.05	0.8	C95
Myeloproliferative disorders	33	0	0	0	0	6.7	0	0	4.2	7.3	4.1	6.7	7.6	6.8	10.3	19.6	4.4	8.4	18.1	26.3	5.3	3	0.27	0.39	4	MPD
Myelodysplastic syndromes	7	0	0	0	0	0	0	0	0	0	0	2.2	0	4.5	0	3.3	4.4	8.4	0	26.3	1.12	0.6	0.03	0.07	0.7	MDS
Other and unspecified	66	0	0	0	0	0	0	2.1	2.1	2.4	6.2	9	15.3	18.2	36.1	42.5	26.3	16.9	54.2	105.1	10.6	6	0.46	0.8	7.1	O&U
All sites	1205	0	0	9	10.8	15.5	26.6	25.1	29.3	53.4	70	139.2	201.2	299.6	456.1	648	829.6	1063.4	1265.6	1654.8	193.48	109.6	6.68	14.07	126.5	ALL
All sites but C44	1099	0	0	6	8.1	15.5	22.5	25.1	27.2	50.9	65.9	128	175.7	272.4	430.3	602.2	741.8	962.1	1175.2	1392.2	176.46	100	6.14	12.86	115.1	ALLbC44

6.1.5 Incidence by 100,000 by age group in 2023 (Female)

SITE	ALL AGES	AGE UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85+	CRUDE RATE	(%)	CUM 0-64	CUM 0-74	ASR	ICD (10th)
Lip	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.4	0	0	0	0	0	0.16	0.1	0.01	0.01	0.1	C00
Tongue	16	0	0	0	0	0	0	0	4.3	0	0	0	5.1	0	16.5	5.7	3.5	5.9	0	12.8	2.51	1	0.13	0.18	1.5	C01-02
Mouth	11	0	0	0	0	0	0	0	0	0	6.4	0	2.6	0	2.4	11.4	3.5	5.9	0	0	1.72	0.7	0.06	0.13	1.1	C03-06
Salivary glands	4	0	0	0	0	0	0	0	0	2.5	0	0	0	0	2.4	0	0	5.9	11	0	0.63	0.3	0.02	0.02	0.4	C07-08
Tonsil	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2.4	5.7	0	0	0	0	0.47	0.2	0.01	0.04	0.3	C09
Other oropharynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	12.8	0.16	0.1	0	0	0.1	C10
Nasopharynx	2	0	0	0	0	0	0	0	2.2	0	0	0	0	2.2	0	0	0	0	0	0	0.31	0.1	0.02	0.02	0.2	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	2.1	0	0	0	0	0	0	0	0	0	0.16	0.1	0.01	0.01	0.1	C12-13
Pharynx unspecified	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2.4	0	3.5	5.9	0	0	0.47	0.2	0.01	0.03	0.2	C14
Oesophagus	9	0	0	0	0	0	0	0	2.2	0	0	2.3	0	4.4	0	0	10.6	0	11	12.8	1.41	0.6	0.04	0.1	0.8	C15
Stomach	42	0	0	0	0	0	0	0	0	0	0	4.6	2.6	8.8	14.2	34.2	17.7	29.5	32.9	51.3	6.58	2.7	0.15	0.41	3.4	C16
Small intestine	8	0	0	0	0	0	0	0	0	2.5	0	0	0	2.2	2.4	0	3.5	5.9	32.9	0	1.25	0.5	0.04	0.05	0.6	C17
Colon	126	0	0	0	2.8	2.3	0	0	2.2	5	10.6	4.6	30.7	19.7	40.1	57	53	112.2	142.6	115.3	19.75	8	0.59	1.14	10.9	C18
Rectum	25	0	0	0	0	0	0	2.1	0	2.5	0	0	0	4.4	11.8	8.5	28.3	5.9	32.9	12.8	3.92	1.6	0.1	0.29	2.1	C19-20
Anus	6	0	0	0	0	0	0	0	0	0	0	4.6	2.6	2.2	0	0	3.5	5.9	0	0	0.94	0.4	0.05	0.06	0.6	C21
Liver	22	0	0	0	0	0	0	0	0	2.5	2.1	2.3	0	6.6	4.7	14.2	14.1	11.8	0	38.4	3.45	1.4	0.09	0.23	1.9	C22
Gallbladder etc.	10	0	0	0	0	0	0	0	0	0	0	2.3	2.6	2.2	7.1	8.5	0	0	11	0	1.57	0.6	0.07	0.11	0.9	C23-24
Pancreas	28	0	0	0	2.8	2.3	2.1	6.4	0	2.5	2.1	6.9	5.1	4.4	7.1	8.5	14.1	0	32.9	0	4.39	1.8	0.21	0.32	3.2	C25
Nose, sinuses etc.	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C30-31
Larynx	9	0	0	0	0	0	0	0	0	0	2.1	2.3	2.6	2.2	0	11.4	0	0	11	0	1.41	0.6	0.05	0.1	0.9	C32
Trachea, bronchus and lung	57	0	0	0	0	0	0	2.1	0	2.5	2.1	11.5	2.6	15.3	30.7	25.6	38.9	23.6	32.9	12.8	8.93	3.6	0.33	0.66	5.1	C33-34
Other thoracic organs	1	0	0	0	0	0	0	0	0	0	0	0	0	2.2	0	0	0	0	0	0	0.16	0.1	0.01	0.01	0.1	C37-38
Bone	4	0	3.2	0	0	0	0	4.3	2.2	0	0	0	0	0	0	0	0	0	0	0	0.63	0.3	0.05	0.05	0.9	C40-41
Melanoma of skin	3	0	0	0	0	0	0	0	0	0	0	0	2.6	2.2	0	0	0	0	0	12.8	0.47	0.2	0.02	0.02	0.3	C43
Other skin	67	0	0	0	0	0	4.2	4.3	0	0	4.2	4.6	12.8	15.3	16.5	19.9	31.8	53.1	76.8	102.5	10.5	4.3	0.31	0.57	5.8	C44
Mesothelioma	2	0	0	0	0	0	0	0	0	0	0	0	0	2.2	0	2.8	0	0	0	0	0.31	0.1	0.01	0.03	0.2	C45
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46
Connective and soft tissue	9	0	0	0	0	0	2.1	0	0	0	0	4.6	0	2.2	9.4	0	3.5	0	0	0	1.41	0.6	0.09	0.11	1	C47,C49
Breast	591	0	0	0	0	0	0	6.4	26	65.2	84.9	114.7	179.3	181.9	179.4	205.2	279.2	277.5	186.5	205	92.64	37.7	4.19	6.61	57.8	C50
Vulva	7	0	0	0	0	0	0	0	0	0	0	2.3	2.6	0	0	0	3.5	5.9	11	25.6	1.1	0.4	0.02	0.04	0.6	C51
Vagina	5	0	0	0	2.8	0	0	0	0	0	0	0	0	4.4	2.4	0	0	0	11	0	0.78	0.3	0.05	0.05	0.6	C52
Cervix uteri	99	0	0	0	0	0	0	0	13	7.5	23.4	25.2	23.1	24.1	18.9	34.2	56.5	47.2	11	38.4	15.52	6.3	0.68	1.13	9.9	C53
Corpus uteri	113	0	0	0	0	0	0	2.1	4.3	2.5	6.4	6.9	28.2	46	56.7	37	60.1	41.3	65.8	51.3	17.71	7.2	0.77	1.25	10.2	C54
Uterus unspecified	23	0	0	0	0	0	0	0	2.2	5	4.2	0	5.1	0	18.9	5.7	10.6	0	32.9	0	3.61	1.5	0.18	0.26	2.2	C55
Ovary	104	0	0	0	2.8	2.3	4.2	6.4	15.1	10	8.5	22.9	30.7	28.5	47.2	31.3	28.3	11.8	32.9	38.4	16.3	6.6	0.89	1.19	11.2	C56
Other female genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C57
Placenta	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C58
Kidney	22	0	0	0	0	2.3	2.1	0	2.2	2.5	0	4.6	0	0	4.7	25.6	7.1	11.8	0	12.8	3.45	1.4	0.09	0.26	2.2	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	15	0	0	0	0	0	0	0	0	5	2.1	0	2.6	6.6	7.1	0	0	11.8	11	25.6	2.35	1	0.12	0.12	1.4	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	3	0	9.6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.47	0.2	0.05	0.05	1.2	C69
Brain, nervous system	50	0	0	0	2.8	0	4.2	0	0	2.5	4.2	6.9	17.9	13.2	9.4	45.6	14.1	23.6	0	0	7.84	3.2	0.31	0.6	5.1	C70-72
Thyroid	22	0	0	0	0	4.6	0	4.3	0	5	4.2	9.2	5.1	2.2	2.4	8.5	3.5	0	11	12.8	3.45	1.4	0.18	0.25	2.7	C73
Adrenal gland	2	0	3.2	0	0	0	0	0	0	0	0	0	0	0	2.4	0	0	0	0	0	0.31	0.1	0.03	0.03	0.5	C74
Other endocrine	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2.4	0	0	0	0	0	0.16	0.1	0.01	0.01	0.1	C75
Hodgkin disease	4	0	0	0	0	0	2.1	0	0	2.5	0	0	0	2.2	0	0	3.5	0	0	0	0.63	0.3	0.03	0.05	0.5	C81
Non-Hodgkin lymphoma	15	0	0	0	0	2.3	2.1	0	0	2.5	2.1	0	2.6	6.6	7.1	2.8	3.5	5.9	11	0	2.35	1	0.13	0.16	1.6	C82-85,C96
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	11	0	0	0	0	0	0	0	0	0	2.1	0	2.6	0	7.1	5.7	3.5	5.9	11	12.8	1.72	0.7	0.06	0.11	1	C90
Lymphoid leukaemia	3	0	6.4	0	0	0	0	0	0	0	0	0	0	0	0	0	3.5	0	0	0	0.47	0.2	0.03	0.05	0.8	C91
Myeloid leukaemia	6	0	0	0	0	0	0	0	0	0	2.1	0	2.6	2.2	2.4	2.8	3.5	0	0	0	0.94	0.4	0.05	0.08	0.6	C92-94
Leukaemia unspecified	8	0	12.8	3.1	2.8	0	0	0	0	2.5	0	0	0	0	0	0	0	5.9	0	0	1.25	0.5	0.11	0.11	2.3	C95
Myeloproliferative disorders	9	0	0	0	0	0	0	0	0	0	0	0	2.6	0	7.1	8.5	7.1	0	0	0	1.41	0.6	0.05	0.13	0.8	MPD
Myelodysplastic syndromes	4	0	0	0	0	0	2.1	0	0	0	0	0	2.6	0	0	5.7	0	0	0	0	0.63	0.3	0.02	0.05	0.5	MDS
Other and unspecified	49	0	3.2	0	0	0	0	2.1	2.2	2.5	4.2	6.9	5.1	11	23.6	22.8	21.2	29.5	21.9	25.6	7.68	3.1	0.3	0.52	4.8	O&U
All sites	1636	0	38.4	3.1	16.6	16.1	25.5	40.4	77.9	135.4	180.5	250	384.2	427.4	571.3	655.5	738.5	749.7	844.9	833	256.45	104.3	10.83	17.8	161.2	ALL
All sites but C44	1569	0	38.4	3.1	16.6	16.1	21.2	36.1	77.9	135.4	176.3	245.4	371.4	412.1	554.8	635.5	706.7	696.6	768	730.5	245.94	100	10.52	17.24	155.5	ALLbC44

6.1.6 Cancer deaths by site and age group in 2023 (Male)

ICD CODE	SITE OF TUMOURS	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C00-C99	**All sites**		**1**	**2**	**1**	**3**	**3**	**6**	**7**	**14**	**21**	**52**	**72**	**95**	**119**	**130**	**96**	**65**	**67**	**754**	**0.95**
C00-C14	**Lip, Oral cavity &Pharynx**			**1**						**1**	**1**	**5**	**7**	**11**	**11**	**4**	**2**	**2**	**3**	**48**	**3.0**
C00	Lip																				
C01,C02	Tongue											1	2	1	7	2	1			14	**2.0**
C03	Gum											1	1							2	**2.0**
C04	Floor of mouth																				
C05,C06	Palate and otherparts of mouth													3	1	1		2	1	8	**2.7**
C07,C08	Parotid and Major Salivary Glands											1					1			2	**0.0**
C09	Tonsil											1		2	1					4	**0.0**
C10	Oropharynx											1		1						2	**0.0**
C11	Nasopharynx			1							1									2	**1.0**
C12,C13	Pyriform sinus&Hypopharynx																				
C14	Ill-defined sites LOP									1			4	4	2	1			2	14	**7.0**
C15-C26	**Digestive Organs**							**2**	**1**	**4**	**7**	**17**	**26**	**33**	**48**	**44**	**36**	**20**	**24**	**262**	**1.4**
C15	Oesophagus										1	2	2	4	4	2	1	3		19	**3.2**
C16	Stomach							1	1	1	1	4	3	5	6	10	4	6	2	44	**2.2**
C17	Small Intestine											**1**			**1**					**2**	**0.7**
C18-C20	Colorectal							1		1	5	5	13	13	17	19	13	6	15	108	**1.2**
C21	Anus & anal canal												1							1	**0.3**

Cancer deaths by site and age group in 2023 (Male)

ICD CODE	SITE OF TUMOUR	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C22	Liver& Intra-hepatic bile ducts									1		3		7	6	7	6	4	2	36	**1.4**
C23-C24	Gall Bladder and otherparts of biliary tract													1	2		2			5	**0.5**
C25	Pancreas									1		2	7	3	10	5	9	1	4	42	**1.6**
C26	Ill-defined Digestive Organs														2	1	1		1	5	**2.5**
C30-C39	**Resp. System & Intra-thoracic Organs**							**1**	**2**	**2**	**4**	**9**	**13**	**21**	**20**	**25**	**15**	**9**	**5**	**126**	**1.9**
C30,C31	Nasal cavity& accessory sinuses															1				1	**0.0**
C32	Larynx											1	4	2	5	2	1	1	1	17	**17.0**
C33-C34	Trachea, Bronchus& Lung							1	2	2	4	7	9	19	15	22	14	8	4	107	**1.7**
C37-C39	Thymus, Heart, mediastinum &pleura, Ill-defined sites resp. system											1								1	**0.0**
C40-C41	Bones & Articular Cartilage						**1**								**1**	**1**		**1**		**4**	**2.0**
C43- C44	Melanoma & other Skin											**4**			**1**	**3**	**3**	**2**		**13**	**2.2**
C45-C49	Mesothelial, Conn. & Soft tissue								**1**					**2**	**1**	**1**		**2**		**7**	**1.0**
C50	Breast															**2**				**2**	**0.0**
C60-C63	**Male Genital Organs**					**1**	**1**	**1**	**1**	**1**		**2**	**4**	**11**	**15**	**24**	**22**	**15**	**25**	**123**	**0.0**
C60,C63	Penis & other MGOs																1			1	**0.0**
C61	Prostate									1		2	4	11	15	24	21	15	25	118	**0.0**
C62	Testis					1	1	1	1											4	**0.0**

Cancer deaths by site and age group in 2023 (Male)

ICD CODE	SITE OF TUMOUR	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C64-C68	**Urinary Tract**									**1**		**2**	**4**	**5**	**6**	**7**	**3**	**4**	**2**	**34**	**2.3**
C67	Bladder											1	4	2	5	1	3	2		18	**4.5**
C64-66,C68	Kidney, Pelvis& Ureter									1		1		3	1	6		2	2	16	**1.5**
C69-C72	**Eye, Brain & other C.N.S**					**1**		**1**			**5**	**4**	**3**	**2**	**5**	**5**	**1**	**1**	**1**	**31**	**1.1**
C69	Eye & adnexa																				
C71	Brain					1					5	4	3	2	5	5	1	1	1	28	**1.2**
C70,C72	Meninges, Spinal Cord& other CNS							1					2							3	0.8
C73-C75	**Thyroid & other Endocrine Glands**								**1**				**1**	**3**		**2**			**1**	**8**	**1.0**
C73	Thyroid Gland													2		1				3	**0.8**
C74-C75	Other Endocrine Glands								1				1	1		1			1	5	**1.3**
C76-C80,C97	**Primary Site Unknown**								**1**	**3**	**1**	**2**	**3**	**3**	**7**	**6**	**7**	**4**	**1**	**38**	**1.0**
C81-C96	**Haematological Malignancies**		**1**	**1**	**1**	**1**	**1**	**1**		**2**	**3**	**7**	**9**	**3**	**3**	**5**	**5**	**4**	**4**	**51**	**1.2**
C81	Hodgkin's Disease				1					1	1	1					1			5	**5.0**
C82-85,C96	NHML			1		1				1		2	2	2	2	1	2	1	1	16	**1.3**
C91-95	Leukaemias		1				1	1			2	2	4		1		2	2	3	19	**1.1**
C88,C90	Multiple Myeloma											2	3	1		4		1		11	**0.9**
	MDS													1	1	1	2	1	1	7	2.3
ALL SITES	**TOTAL**	**0**	**1**	**2**	**1**	**3**	**3**	**6**	**7**	**14**	**21**	**52**	**72**	**95**	**119**	**130**	**96**	**65**	**67**	**754**	**0.95**

6.1.7 Cancer deaths by site and age group in 2023 (Female)

ICD CODE	SITE OF TUMOURS	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C00-C99	**All sites**	**2**	**3**	**3**	**2**	**6**	**3**	**10**	**12**	**28**	**35**	**50**	**87**	**97**	**115**	**114**	**92**	**62**	**70**	**791**	**0.95**
C00-C14	**Lip, Oral cavity & Pharynx**										**1**	**3**	**3**		**2**	**3**	**2**	**1**	**1**	**16**	**3.0**
C00	Lip																				
C01,C02	Tongue												1		2		2	1	1	7	**2.0**
C03	Gum												1							1	**2**
C04	Floor of mouth															1				1	**0**
C05,C06	Palate and otherparts of mouth										1	1				1				3	**2.7**
C07,C08	Parotid and Major Salivary Glands																				
C09	Tonsil																				
C10	Oropharynx																				
C11	Nasopharynx											1	1							2	**1.0**
C12,C13	Pyriform sinus&Hypopharynx																				
C14	Ill-defined sites LOP											1				1				2	**7.0**
C15-C26	**Digestive Organs**						**1**	**1**	**3**	**7**	**9**	**7**	**13**	**20**	**23**	**36**	**24**	**23**	**20**	**187**	**1.4**
C15	Oesophagus													1		5				6	**3.2**
C16	Stomach									2	3	2	1	1	4	2	3		2	20	**2.2**
C17	Small Intestine																	3		3	**0.7**
C18-C20	Colorectal						1	1	1	2	1	4	5	9	12	17	14	12	12	91	**1.2**
C21	Anus & anal canal										2							1		3	**0.3**
C22	Liver& Intra-hepatic bile ducts								1	2	1		4	3	2	3	3	3	3	25	**1.4**

Cancer deaths by site and age group in 2023 (Female)

ICD CODE	SITE OF TUMOURS	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C23-C24	Gall Bladder									1				3	2	3	1	1		11	**0.5**
C25	Pancreas								1		2	1	3	3	3	6	2	2	3	26	**1.6**
C26	Ill-defined Digestive Orgs																1	1		2	**2.5**
C30-C39	**Resp. System & Intrathoracic Organs**						**1**	**1**		**3**	**1**	**3**	**10**	**9**	**6**	**11**	**8**	**6**	**6**	**65**	**1.9**
C30,C31	Nasal cavity&acessory organs																				
C32	Larynx																	1		1	**17.0**
C33-C34	Trachea, Bronchus& Lung						1	1		3	1	3	10	9	6	11	8	5	6	64	**1.7**
C37-C39	Thymus, Heart, mediastinum & pleura, Ill-def site resp sys																				
C40-C41	Bones & Articular Cartilage											1				1				**2**	**2**
C43-C44	Melanoma & other Skin								1					1			1		3	**6**	**2.2**
C45-C49	Mesothelial, Conn. & Soft Tissue									1	1		3		1		1			**7**	**1.0**
C50	**Breast**							5	5	11	16	18	23	27	38	18	25	14	25	**225**	**0.0**
C51-C58	**Female Genital Organs**			**1**				**2**	**1**	**2**	**6**	**10**	**20**	**25**	**30**	**22**	**13**	**7**	**9**	**147**	
C51-C52	Vulva,Vagina												1		2	1	1	2		7	
C53	Cervix Uteri							2				2	8	7	4	5	4	1	4	37	
C54	Corpus Uteri									1	3	1	3	8	15	8	6	4	2	51	
C56	Ovary			1					1	1	2	7	8	9	9	8	2		3	51	

Cancer deaths by site and age group in 2023 (Female)

ICD CODE	SITE OF TUMOURS	0-4 yrs	5-9 yrs	10-14 yrs	15-19 yrs	20-24 yrs	25-29 yrs	30-34 yrs	35-39 yrs	40-44 yrs	45-49 yrs	50-54 yrs	55-59 yrs	60-64 yrs	65-69 yrs	70-74 yrs	75-79 yrs	80-84 yrs	85+	TOTAL	SEX Ratio
C57-C58	OAU Female Genital Organs													1						1	
C64-C68	**Urinary Tract**	**1**			**1**		**1**							**1**	**2**	**2**	**5**	**1**	**1**	**15**	**2.3**
C67	Bladder														1	1	1		1	4	**4.5**
C64-66,C68	Kidney, Pelvis& Ureter	1			1		1							1	1	1	4	1		11	**1.5**
C69-C72	**Eye, Brain & other C.N.S**		**1**	**2**		**2**				**1**		**3**	**5**	**3**	**3**	**6**	**1**	**1**		**28**	**1.1**
C69	Eye & adnexa																				
C71	Brain		1	2		2				1		3	4	3	3	3	1	1		24	**1.2**
C70,C72	Meninges, Spinal Cord & other CNS												1			3				4	0.8
C73-C75	**Thyroid&other Endo Glands**		**1**					**1**	**1**					**1**	**1**	**1**	**2**			**8**	**1.0**
C73	Thyroid Gland							1							1		2			4	**0.8**
C74-C75	Other Endocrine Glands		1						1					1		1				4	**1.3**
C76-C80,C97	**Primary Site Uncertain**	1				1			1	2	1	4	5	6	1	6	6	5	1	**40**	**1.0**
C81-C96	**Haematological Malignancies**		**1**	**1**		**3**				**1**	**1**	**1**	**5**	**4**	**7**	**8**	**3**	**4**	**3**	**42**	**1.21**
C81	Hodgkin's Disease													1						1	**5.0**
C82-85,C96	NHML					1							4		2	2		1	2	12	**1.3**
C91-95	Leukaemias		1	0	1	2				1				2	4	2	1	2	1	17	**1.1**
C88,C90	Multiple Myeloma										1	1	1	1	1	4	2	1	0	12	**0.9**
MPD	Myeloproliferative disorders														1		1		1	**3**	**2.3**
All Site	**TOTAL**	**2**	**3**	**3**	**2**	**6**	**3**	**10**	**12**	**28**	**35**	**50**	**87**	**97**	**115**	**114**	**92**	**62**	**70**	**791**	**0.95**